Journal article

Combined BRAF and MEK inhibition in BRAF-mutant NSCLC

Gareth Rivalland, Paul Mitchell

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2016

DOI: 10.1016/S1470-2045(16)30203-0

University of Melbourne Researchers

Citation metrics

2Web of Science
3Scopus

Keywords

Cell Lung-Cancer
Science & Technology
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Open-Label
Life Sciences & Biomedicine
Melanoma
Mutation
Dabrafenib
Protein Kinase Inhibitors
Multicenter
Randomized Controlled-Trial
Proto-Oncogene Proteins B-Raf
Cell Line, Tumor
Oncology
Trametinib
Humans